Clinical Trials
Page 3 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Newleos Begins Phase 1b Trial of NTX-2001 for Alcohol Use Disorder Treatment
Newleos doses first patient in Phase 1b study of NTX-2001, a TAAR1 partial agonist targeting alcohol use disorder, marking key development milestone.
Clinical Trial Regulatory Harmonization: NMPA & PMDA ICH Adoption in APAC
This article delves into the regulatory harmonization of clinical trials in APAC, focusing on NMPA and PMDA's ICH adoption to expedite drug approvals.
Clinical Trial Quality Management Systems: New APAC Standards & Challenges
This article delves into the latest APAC standards for clinical trial quality management systems, highlighting challenges in ensuring drug efficacy and patient safety.
China Clinical Trial Regulations: Key Insights on NMPA Reforms 2024
Discover key insights on the 2024 NMPA reforms in China, shaping clinical trial regulations and their implications for drug development in oncology and rare diseases.
NMPA Foreign Clinical Trial Data: What You Need to Know
This article explores the significance of NMPA foreign clinical trial data for drug approvals, focusing on its impact on cancer therapies and regulatory compliance.
TrialClinIQ Secures $150K Investment from Caduceus Capital to Transform Clinical Trial Recruitment with AI Technology
Houston-based TrialClinIQ raises $150K pre-seed funding and joins LAUNCH accelerator while opening $1.5M round to improve clinical trial access through AI.
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
Argo Biopharma begins Phase I clinical trial of BW-50218, an siRNA therapeutic targeting transthyretin protein for rare disease treatment in Australia.
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
Sunnybrook Health Sciences Centre Receives $41 Million Investment to Expand Clinical Trials Infrastructure in Canada
Sunnybrook Health Sciences Centre announces $41M philanthropic investment to expand clinical trials capacity and strengthen Canada's position in global research.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Samsung Bioepis launches first-in-human trial for ADC candidate SBE303 and expands Sandoz partnership for five biosimilars including vedolizumab.